Novel outcome measures for Charcot−Marie−Tooth disease: validation and reliability of the 6-min walk test and StepWatch™Activity Monitor and identification of the walking features related to higher quality of life

Autor: Padua, L., Pazzaglia, C., Pareyson, D., Schenone, A., Aiello, A., Fabrizi, G. M., Cavallaro, T., Santoro, L., Manganelli, F., Gemignani, F., Vitetta, F., Quattrone, A., Mazzeo, A., Russo, M., Vita, G, Gentile, L, Messina, S, Stancanelli, C, L Vita, G, Iacovelli, C, Figliolia, D, Silipo, S, Cabrini, I, Pisciotta, C, Tozza, S, Contini, M
Přispěvatelé: Padua, L., Pazzaglia, C., Pareyson, D., Schenone, A., Aiello, A., Fabrizi, G. M., Cavallaro, T., Santoro, Lucio, Manganelli, Fiore, Gemignani, F., Vitetta, F., Quattrone, A., Mazzeo, A., Russo, M., Vita, G.
Rok vydání: 2016
Předmět:
Male
030506 rehabilitation
medicine.medical_treatment
Validity
Walking
Disease
Outcome measure
0302 clinical medicine
Quality of life
Charcot-Marie-Tooth Disease
Outcome Assessment
Health Care
Charcot−Marie−Tooth
outcome measures
quality of life
rehabilitation
Prospective Studies
Prospective cohort study
Reliability (statistics)
Rehabilitation
Charcot-Marie-Tooth
Outcome measures
Neurology (clinical)
Neurology
Middle Aged
Test (assessment)
Settore MED/26 - NEUROLOGIA
Italy
Female
0305 other medical science
Adult
congenital
hereditary
and neonatal diseases and abnormalities
medicine.medical_specialty
Adolescent
Monitoring
MEDLINE
Walk Test
Outcome Assessment (Health Care)
Young Adult
03 medical and health sciences
Physical medicine and rehabilitation
medicine
Humans
Physiologic
Monitoring
Physiologic
Aged
business.industry
Charcot−Marie−Tooth
Reproducibility of Results
Quality of Life
Charcotâ Marieâ Tooth
nervous system diseases
Physical therapy
business
030217 neurology & neurosurgery
Settore MED/34 - MEDICINA FISICA E RIABILITATIVA
Zdroj: European Journal of Neurology. 23:1343-1350
ISSN: 1351-5101
Popis: Background and purpose Charcot−Marie−Tooth (CMT) disease is the most common inherited neuropathy, but therapeutic options have been limited to symptom management. Past pharmacological trials have failed, possibly due to insensitive outcome measures (OMs). The aim of the current study was to evaluate the validity and reliability of the 6-min walk test (6MWT) and StepWatch™ Activity Monitoring (SAM) with other previously validated OMs in CMT disease. Methods A prospective multicenter study was performed, consecutively enrolling 168 CMT patients (104 with CMT1A, 27 with CMT1B, 37 with X-linked CMT) from Italian centers specializing in CMT care. Results Statistical analysis showed that the 6MWT was highly related with all previously used OMs. Some, but not all, SAM parameters were related to commonly used OMs but may provide more information about quality of life. Conclusions The current study demonstrated the validity and reliability of the 6MWT and SAM as OMs for CMT. Moreover, SAM provides data that correlate better with quality of life measures, making it useful in future rehabilitation trials.
Databáze: OpenAIRE
Externí odkaz: